• 作者：Ignacio J. Sá ; nchez Lá ; zaro^a ; ^{ignaciosanchezlazaro@gmail.com} ; Luis Almenar Bonet^a ; Luis Martí ; nez Dolz^a ; Francisco Buendí ; a Fuentes^a ; Josep Navarro Manchó ; n^a ; Jaime Agü ; ero Ramó ; n-Llin^a ; José ; Luis Vicente Sá ; nchez^b ; Antonio Salvador Sanz^a
• 关键词：Trasplante cardiaco ; Daclizumab ; Inhibidor de la calcineurina
• 刊名：Revista Espa帽ola de Cardiolog铆a
• 出版年：2011
• 期刊代码：pca308_03008932
• 类别：med
• 出版时间：March 2011
• 卷：64
• 期：3
• 页码：237-239
• 文件大小：83 K

Daclizumab is an interleukin-2 receptor antagonist which is used for induction therapy in heart transplant patients. It has few side effects and is associated with a low infection rate. Postoperative renal failure after heart transplantation is common and potentially fatal. The administration of calcineurin inhibitors in the postoperative period can aggravate the situation. We report the cases of six patients who underwent heart transplantation and developed acute renal failure in the immediate postoperative period. All were administered daclizumab weekly to avoid the introduction of calcineurin inhibitors and to facilitate recovery of renal function. Calcineurin inhibitors were introduced only once renal function had improved. Renal function recovered in all cases and there was a low complication rate. The administration of repeated doses of daclizumab to patients who experience acute postoperative renal failure after heart transplantation may provide an alternative therapeutic approach that enables calcineurin inhibitors to be avoided and, consequently, renal function to recover.

Full English text available from: